Back to top
more

Natera (NTRA)

(Delayed Data from NSDQ)

$175.01 USD

175.01
801,015

+2.85 (1.66%)

Updated Sep 16, 2025 04:00 PM ET

Pre-Market: $175.00 -0.01 (-0.01%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 245)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Natera Shares Rise on the Launch of AI Platform for Precision Oncology

by Zacks Equity Research

NTRA shares gain after unveiling its in-house AI platform, built on vast oncology datasets to transform precision cancer care.

Zacks Equity Research

Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of -23.33% and +15.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pediatrix Medical Group (MD) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of +26.19% and +0.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medpace (MEDP) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of +3.33% and +11.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 Release

by Urmimala Biswas

TEM's revenue and gross profit are climbing fast as new AI tools and data services boost margins ahead of Q2 earnings.

Zacks Equity Research

Should Vanguard Small-Cap Growth ETF (VBK) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VBK

Zacks Equity Research

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Zacks Equity Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Zacks Equity Research

Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 15.25% and 13.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enhabit (EHAB) Q1 Earnings Top Estimates

by Zacks Equity Research

Enhabit (EHAB) delivered earnings and revenue surprises of 42.86% and 2.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pediatrix Medical Group (MD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 32% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PBE

Zacks Equity Research

Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 2.38% and 0.88%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DENTSPLY SIRONA to Post Q4 Earnings: What's in Store for the Stock?

by Zacks Equity Research

XRAY is likely to have faced a tough fourth quarter with Byte's revenue loss, weak U.S. equipment demand and implant pressures.

Zacks Equity Research

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Gilead Sciences (GILD) and Natera (NTRA) have performed compared to their sector so far this year.

Zacks Equity Research

HSIC Gears Up for Q4 Earnings: Here's What You Need to Know

by Zacks Equity Research

Henry Schein is expected to report impressive sales in both its businesses in the fourth quarter of 2024, along with a positive pace of recovery from the cyber incident.

Zacks Equity Research

Natera (NTRA) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Will BAX's Q4 Earnings Reflect Its Efforts to Counter Headwinds?

by Zacks Equity Research

Baxter might have faced fourth-quarter hurdles from Hurricane Helene. However, it expects growth in infusion therapies, pharmaceuticals and patient support systems to have driven recovery.

Zacks Equity Research

DXCM Q4 Earnings to Reflect Market Expansion & Stelo Impact?

by Zacks Equity Research

DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, driving momentum and market expansion into 2025.

Zacks Equity Research

GEHC Q4 Earnings: Will Robust Procedures Help Offset Chinese Weakness?

by Zacks Equity Research

GEHC's fourth-quarter results are likely to reflect mixed segmental performance in imaging, advanced visualization solutions and patient care. Pharma is likely to have been the key driver.

Zacks Equity Research

Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?

by Zacks Equity Research

West Pharmaceutical Services eyes fourth-quarter growth amid pharma stabilization, biologics rebound & contract manufacturing gains. Can WST sustain its momentum?